Jo, J., Ham, A., Lee, K. E., Lee, D. H. (2026). Pre-progression discontinuation and off-treatment progression-free interval after enfortumab vedotin–based therapy among patients with clinical benefit in advanced urothelial carcinoma: A single-institution experience.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.e16593